Sign in

Canadian VIGOUR Centre

@cvcualberta.bsky.social
69 followers 125 following 25 posts

The Canadian VIGOUR Centre (CVC) is an academic research organization at the University of Alberta dedicated to enhancing cardiovascular health.

PostsRepliesMedia
Reposted by Canadian VIGOUR Centre
The Journal of Physiology @jphysiol.bsky.social · 22/09/2026
In this study, Andrew W. D'Souza from @ualbertadom.bsky.social and colleagues investigated differential effects of central blood volume loading and unloading on #pulmonary diffusing capacity in humans 🫁 🔎 Read the conclusions👇️ physoc.onlinelibrary.wiley.com/doi/10.1113/...
001
Reposted by Canadian VIGOUR Centre
PLOS Medicine @plosmedicine.org · 21/08/2026
In a remotely conducted, randomized clinical trial with participants spanning 13 countries, Emily Johnson and colleagues find that a multicomponent digital intervention coupled with human support can reduce #anxiety and #depression in persons with chronic conditions🧪 plos.io/4hMHTMG
plos.io
Effect of a digital intervention on mental health symptoms in adults with chronic conditions: A three-arm randomized controlled trial
Author summary Why was this study done? Anxiety, depression, and fatigue are highly prevalent across chronic medical conditions and are major drivers of disability and reduced quality of life. Ac...
021
Reposted by Canadian VIGOUR Centre
gabrielsteg.bsky.social @gabrielsteg.bsky.social · 31/08/2026
Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial academic.oup.com/eurjpc/artic...
academic.oup.com
Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial
Elevated levels of lipoprotein(a) [Lp(a)] are associated with an increased risk of atherothrombotic cardiovascular events. Yet, uncertainty persists regard
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 21/08/2026
New from @rci.bsky.social: What to do if you witness a cardiac arrest. 🫀 Contributors, including CVC Faculty Drs. Roopinder Sandhu & Sean van Diepen, explain how to spot the signs, start basic CPR, and why quick action could save lives.
000
Reposted by Canadian VIGOUR Centre
JAMA @jama.com · 28/07/2026
Among adults with CKD stage 4/5 or on dialysis, low-dose rivaroxaban did not lower cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group. ja.ma/3TgP0Tp
JAMA clinical trial summary: Low-dose rivaroxaban did not reduce cardiovascular events in 1458 advanced CKD patients (22.6% vs 20.7% for placebo), but increased major bleeding (8.8% vs 6.0%). Mean age 63. Trial across 90 centers worldwide.
032
Canadian VIGOUR Centre @cvcualberta.bsky.social · 17/06/2026
Current PAH treatments improve outcomes, but remission remains a critical gap. Experts call for novel biomarkers, refined trial designs, & targeting reverse remodeling to optimize patient care. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...
000
Reposted by Canadian VIGOUR Centre
JAMA Cardiology @jamacardiology.com · 06/06/2026
From @jama.com: Among adults with advanced chronic #kidney #disease (#CKD) stage 4 or 5 or on #dialysis, low-dose rivaroxaban did not lower #cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group. ja.ma/4uOPe1P
JAMA study: Low-dose rivaroxaban did not reduce cardiovascular events in advanced CKD patients (22.6% vs 20.7% placebo, HR 1.09) but increased major bleeding (8.8% vs 6.0%). 1458 patients (1026M, 432F) mean age 63.
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 05/06/2026
A recent retrospective cohort study explored the frequency of elevated biomarkers & new clinical cardiac diagnoses in patients hospitalized with influenza or Covid-19. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...
000
Reposted by Canadian VIGOUR Centre
JAMA Network Open @jamanetworkopen.com · 24/05/2026
In a randomized trial, #Email recruitment increased research participant engagement more than patient portal messaging; message content (altruistic vs individualistic) had no significant overall effect. ja.ma/3Rp5eJ6
JAMA Network Open article: "Messaging Modality and Content for Recruitment of Research Participants: A Randomized Clinical Trial" by Pishoy Gouda et al. Published online May 22, 2026. doi:10.1001/jamanetworkopen.2026.14046
001
Reposted by Canadian VIGOUR Centre
JAMA Network Open @jamanetworkopen.com · 17/05/2026
In acute #HeartFailure, a risk-stratified emergency department and postdischarge care strategy was equally effective in both females and males for reducing cardiovascular hospitalization or death. ja.ma/49BflAE
Two graphs show unadjusted cumulative incidence over time for females (A) and males (B). Each graph plots control and intervention groups. In both genders, incidence increases over 30 days, with some divergence between the groups.
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 08/05/2026
The spring issue of the Canadian Cardiac Chronicle Newsletter is now available! Read more about our current trials, research highlights, & other recent news & updates here ➡️: tinyurl.com/65fbuvfa
000
Reposted by Canadian VIGOUR Centre
CJC Journals @cjcjournals.bsky.social · 07/05/2026
❤️ Looking for resources in honour of Heart Failure Awareness Week? Don’t miss our curated collection of articles! ⬇️ ccs.ca/wp-content/u... #CardioSky #CJC #CJCO #CJCPC
011
Canadian VIGOUR Centre @cvcualberta.bsky.social · 29/04/2026
In this highlighted review, Dr. Sean van Diepen & co-authors examine epidemiological data to propose a framework for the classification & management of mixed cardiogenic shock. Learn about this research & more in our 2025 Annual Report: thecvc.ca/annual-repor...
000
Reposted by Canadian VIGOUR Centre
Duke Clinical Research Institute @dcrinews.bsky.social · 17/04/2026
New peer‑reviewed research led by the Precision Health Alliance, coordinated by DCRI, outlines the ethical and regulatory considerations for responsibly advancing gene-editing therapies in precision medicine. dcri.org/news/new-pub... #ClinicalResearch #PrecisionMedicine #GeneEditing #Bioethics
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 16/04/2026
The STRIVE trial found low-dose alteplase does not reduce microvascular obstruction in high-risk STEMI patients. With no clinical advantage & potential safety risks, routine use is not recommended. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...
000
Canadian VIGOUR Centre @cvcualberta.bsky.social · 07/04/2026
Currently accepting applications for the CVC Scholar Program! 🔬 This program is a unique training opportunity to enhance your research expertise & career in cardiovascular medicine. Learn more & apply here: thecvc.ca/programs-and... #CardioSky
001
Reposted by Canadian VIGOUR Centre
JAMA Network Open @jamanetworkopen.com · 06/04/2026
Among Medicare beneficiaries, acute myocardial infarction incidence declined during and after the COVID-19 pandemic; mortality increased during the pandemic and then improved, especially in urban populations. ja.ma/48eNu8I
Four bar graphs show rate per 1000 person-years based on self-rated health. Graphs A and B show "Cardiovascular events in women" and "All-cause death in women" respectively. C and D show same metrics for men. For both genders, rates rise from 'Excellent' to 'Fair to poor'.
001
Reposted by Canadian VIGOUR Centre
CMAJ @cmaj.ca · 31/03/2026
Management of brain–heart multimorbidity guideline: This clinical practice guideline expands on current cardiovascular guidelines to include evidence from the neurologic and mental health literature. ➡️ www.cmaj.ca/lookup/doi/10.1503/cmaj.251137
012
Canadian VIGOUR Centre @cvcualberta.bsky.social · 23/03/2026
Alberta data shows maternal asthma increases risks of preterm birth, low birth weight, & C-sections—with highest risks tied to active asthma & specific inflammatory phenotypes. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...
010
Canadian VIGOUR Centre @cvcualberta.bsky.social · 12/03/2026
New meta-analysis data suggests rethinking transfusion strategies for patients with heart attack & anemia. Restrictive strategies were linked to higher cardiac mortality & lower 6-month survival. Learn about this research & more in our 2025 Annual Report: thecvc.ca/annual-repor...
000
Canadian VIGOUR Centre @cvcualberta.bsky.social · 05/03/2026
Pooled data from the VICTOR & VICTORIA trials demonstrates vericiguat reduces CV death & HF hospitalizations across the HFrEF spectrum—from stable to recently worsened cases. Learn about this research & other highlights in the 2025 CVC Annual Report: thecvc.ca/annual-repor...
000
Reposted by Canadian VIGOUR Centre
HCPLive @hcplivenews.bsky.social · 20/02/2026
We spoke with Justin Ezekowitz, MD, to discuss his recent analysis of the SODIUM-HF trial, which indicated that dietary salt limitations may only benefit patients at the lowest risk for heart failure, contrary to popular belief. Watch now:
hcplive.com
Sodium Restrictions May Only Benefit Patients at Low Risk of HF, With Justin Ezekowitz, MD | HCPLive
Ezekowitz discusses his recent secondary analysis of the SODIUM-HF trial, highlighting the MAGGIC analysis data that implied a very limited benefit.
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 18/02/2026
We’re pleased to share our 2025 Annual Report: The Arteries of Innovation. Innovation thrives on the circulation of diverse ideas. Discover how the CVC translates high-quality data into clinical solutions bridging the gap from discovery to care. Read the report here➡️: thecvc.ca/annual-repor...
000
Reposted by Canadian VIGOUR Centre
JAMA Cardiology @jamacardiology.com · 06/02/2026
Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. bit.ly/4alEy1P
Two graphs compare bleeding with abelacimab vs. rivaroxaban. Graph A: bar graph shows incidence rate per 100 patient-years stratified by age. Graph B: probability of major bleeding vs. age for rivaroxaban and abelacimab pooled dose.
001
Reposted by Canadian VIGOUR Centre
The Canadian Cardiovascular Society @ccs-scc.bsky.social · 27/01/2026
Registration is open for the next webinar in our ASCVD Education Series, taking place Thursday, January 29, 2026, at 8:00 p.m. ET. Join us as experts explore evidence‑based strategies to enhance patient outcomes and support best practices in ASCVD management. Register today🔗https://bit.ly/3ZynKiT
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 21/01/2026
In this @jamacardiology.com .com viewpoint, Drs. Armstrong, Bainey, & Granger advocate for aligning #STEMI time metrics with current first-point-of-contact capabilities to ensure optimized outcomes for all patients, regardless of geographic location. jamanetwork.com/journals/jam...
jamanetwork.com
Coronary Reperfusion in Patients With ST-Elevation MI Requiring Transfer
This Viewpoint evaluates the evolution of ST-elevation myocardial infarction guidelines on reperfusion choices and the evidence that adherence to timely reperfusion recommendations affects outcomes in...
000
Reposted by Canadian VIGOUR Centre
American College of Cardiology @accintouch.bsky.social · 06/01/2026
The VICTOR study results complement those of the VICTORIA by extending the evidence base for vericiguat in a contemporary lower-risk, well-treated ambulatory #HFrEF population. Explore more insights from the VICTOR trial ➡️ bit.ly/4blPC0O #HeartFailure
bit.ly
Vericiguat in Heart Failure: Insights From the VICTOR Trial - American College of Cardiology
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 16/12/2025
The winter issue of the Canadian Cardiac Chronicle Newsletter is now available! Read more about our current trials, research highlights, & other recent news & updates here: mailchi.mp/bed47c9edc60...
010
Canadian VIGOUR Centre @cvcualberta.bsky.social · 27/11/2025
Now accepting applications! The CVC Scholar Program is a unique training opportunity for early-stage investigators focused on cardiovascular disease research. Learn more & apply ➡️: thecvc.ca/programs-and... #cardiosky #cardiology
010
Reposted by Canadian VIGOUR Centre
NEJM.org @nejm.org · 07/11/2025
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo @asnkidney.bsky.social | #KidneyWk
American Society of Nephrology Kidney Week 2025 
Original Article | Nov. 7, 2025 | NEJM.org 
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis 

Fig. 1A. A Serious Cardiovascular Events 

The NEJM identity sits at the bottom.
22511
Canadian VIGOUR Centre @cvcualberta.bsky.social · 31/10/2025
Congratulations to CVC Co-Director Dr. Padma Kaul, who has been named Tier 1 Canada Research Chair in Women and Children’s Cardio-Metabolic Health. 👏 www.ualberta.ca/en/the-quad/...
ualberta.ca
Meet the U of A's Fall 2025 Canada Research Chairs
010
Reposted by Canadian VIGOUR Centre
EuroIntervention @eurointervention.bsky.social · 24/10/2025
In STEMI patients with multivessel disease, reduced LVEF increases ischaemic risk — but the COMPLETE trial showed complete revascularisation reduces major CV events regardless of LVEF. #cardiosky #medsky #LVEF #cardiology eurointervention.pcronline.com/article/impa...
014
Reposted by Canadian VIGOUR Centre
The Canadian Cardiovascular Society @ccs-scc.bsky.social · 20/10/2025
🚨 Just published! This guideline provides multi-disciplinary clinical teams with practical recommendations for SGLT2is, MRAs, ARNI and drugs with GLP-1 receptor agonist activity. Read the guideline here: onlinecjc.ca/article/S082... #Cardiosky #HeartFailure
036
Reposted by Canadian VIGOUR Centre
HCPLive @hcplivenews.bsky.social · 18/10/2025
At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF. Watch now:
hcplive.com
Vericiguat Improves HFrEF Regardless of Background Therapy, With Justin Ezekowitz, MD | HCPLive
Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 08/10/2025
❣️The Fall 2025 issue of the CVC Chronicle newsletter is now available❣️ Read about our current trials, research highlights, & other recent news/updates here: tinyurl.com/3w4srx67
010
Canadian VIGOUR Centre @cvcualberta.bsky.social · 06/10/2025
Women with asthma, particularly active asthma, are at higher risk for preterm birth, low birth weight, & C-section, highlighting the need for improved asthma monitoring & management during pregnancy. @wchriuofa.bsky.social @stollerykids.bsky.social @ualberta.bsky.social
ualberta.ca
Maternal asthma a risk for babies, study shows
A University of Alberta-led research team has identified an association between asthma in pregnant women and adverse outcomes for their newborns, including preterm birth, low birth weight and caesarea...
010
Reposted by Canadian VIGOUR Centre
David Collister @turbodc.bsky.social · 25/09/2025
Dr. Moorthy reviewing the WHO global action plan for clinical trial ecosystem strengthening at the 4th Annual ACT meeting in Cape Breton, NS. We are making progress in Canada but lots of work to do! @cvcualberta.bsky.social @csnscn.bsky.social @ualberta.bsky.social
111
Canadian VIGOUR Centre @cvcualberta.bsky.social · 18/09/2025
New analysis published in @jcardfail.bsky.social: applying the 5-STAR risk stratification method to VICTORIA trial data revealed a greater treatment effect for vericiguat on the composite endpoint of CV death or HF hospitalization. Read more ➡️: authors.elsevier.com/a/1llYy3pkRz...
010
Reposted by Canadian VIGOUR Centre
Jason Weatherald, MD 🇨🇦 @albertaphdoc.bsky.social · 06/09/2025
Happy to have had the chance to contribute to this amazing collaborative work led by @sandeepsahaymd.bsky.social and Dr Ray Benza
052
Reposted by Canadian VIGOUR Centre
The Lancet @thelancet.com · 29/08/2025
Heart failure affects more than 55 million people worldwide. 🫀 A new Lancet Series, presented at #ESC2025, serves as a call to action for clinicians, health systems, and governments to prioritise the primary prevention of heart failure. tinyurl.com/2sty9386
Figure highlighting selected opportunities for promotion of CKM health and prevention of heart failure at the individual, health-care system and community, and population and policy levels. CKM=cardiovascular-kidney-metabolic. Copyright: 2025 Elsevier Ltd. All rights reserved.
3129
Reposted by Canadian VIGOUR Centre
American College of Cardiology @accintouch.bsky.social · 30/08/2025
Late-breaking science from VICTOR & VICTORIA trials presented at #ESCCongress add to growing body of evidence surrounding vericiguat in treating patients with HFrEF. Read more: bit.ly/4lTUNXE #HeartFailure
014
Reposted by Canadian VIGOUR Centre
JACC Journals @jaccjournals.bsky.social · 30/08/2025
In #HFrEF, quadruple therapy (ARNi, β-blockers, MRA, #SGLT2i) improves survival. Adding #vericiguat may offer a modest ~0.7-year gain, though findings are exploratory, as they are derived from a secondary endpoint of a single trial bit.ly/4mE83Rp #JACC #ESCCongress #WCCardio
066
Canadian VIGOUR Centre @cvcualberta.bsky.social · 21/08/2025
The AURORA study is currently recruiting adults & adolescents with type 1 diabetes (T1D) & caregivers for an advisory group. Share your experience navigating the Alberta healthcare system & help us create a vital T1D knowledge hub! Learn more ➡️: thecvc.ca/aurora-recru...
010
Reposted by Canadian VIGOUR Centre
Jason Weatherald, MD 🇨🇦 @albertaphdoc.bsky.social · 05/08/2025
Excited to finally share our James Lind Alliance #Top10 Research Priorities for #LungTransplantation 🫁🔬👩🏽‍🔬 @ualberta.bsky.social @ubcmedicine.bsky.social @umontreal.ca @uhnresearch.ca @ucalgarymed.bsky.social www.jhltopen.org/article/S295...
jhltopen.org
Priorities for lung transplantation research: a James Lind Alliance priority-setting partnership between patients, caregivers, and clinicians in Canada
This study employed the James Lind Alliance Priority Setting Partnership methodology to identify and prioritize research priorities in lung transplantation through engagement of pre- and post-lung tra...
021
Reposted by Canadian VIGOUR Centre
TCTMD @tctmd.bsky.social · 02/08/2025
Patients hospitalized with influenza are just as likely as COVID-19 patients to have signs of myocardial involvement. Lead study author Finlay McAlister said the findings show a need to screen and monitor patients more closely. www.tctmd.com/news/cardiac...
tctmd.com
Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza
Patients who are hospitalized for either viral infection should be screened for myocardial involvement, experts say.
001
Canadian VIGOUR Centre @cvcualberta.bsky.social · 15/07/2025
New in @jaccjournals.bsky.social: A secondary analysis of the VICTORIA trial investigates the impact of geographic variation and Human Development Index on heart failure outcomes. 🫀 🌏 Read more here: www.sciencedirect.com/science/arti...
010
Reposted by Canadian VIGOUR Centre
CJC Journals @cjcjournals.bsky.social · 25/06/2025
💭 Review of transcatheter aortic valve insertion (#TAVI) clinician opinions on the CCS Post-TAVI Driving Guidelines: is a 1-month driving restriction period overly cautious? Read more ⬇️ cjcopen.ca/article/S258... #CJCO #OpenAccess
001
Reposted by Canadian VIGOUR Centre
JAMA Network Open @jamanetworkopen.com · 17/06/2025
Among patients with opioid-associated out-of-hospital cardiac arrest, chest compression and ventilation CPR was associated with a higher odds of favorable neurologic outcomes at hospital discharge. ja.ma/4l7We4q
043
Reposted by Canadian VIGOUR Centre
phaware® @phaware.bsky.social · 10/06/2025
Dr. Jason Weatherald explains how your everyday clinic visits can help shape the future of pulmonary hypertension treatment. @phaware.bsky.social podcast ep 524 @phacanada #phawareMD @teamphhope @albertaphdoc.bsky.social @ualberta.bsky.social medium.com/p/im-aware-t...
medium.com
I’m Aware That I’m Rare: Jason Weatherald, MD (524)
the phaware® interview
022
Reposted by Canadian VIGOUR Centre
The Canadian Cardiovascular Society @ccs-scc.bsky.social · 05/06/2025
🫀 Join us June 11 for our webinar: Heart-Healthy Eating: Evidence-Based Nutrition for Cardiovascular Health! 🔗 Register now! ow.ly/yBOO50W5aZP #cardiosky
042